MarketPulse

obesity drugs

11 articles
The Motley FoolThe Motley Fool··James Brumley

Viking Therapeutics Stock Could Double as GLP-1 Rival Advances Toward FDA Approval

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.
LLYNVOVKTXFDA approvalPhase 3 trials
BenzingaBenzinga··Vandana Singh

Kailera's $625M IPO Signals Renewed Investor Appetite for GLP-1 Obesity Treatments

Kailera Therapeutics raised $625M in largest biotech IPO since 2021, entering competitive obesity market with oral GLP-1 candidate showing 12.1% weight loss.
LLYNVOSANAIPObiotech
BenzingaBenzinga··Vandana Singh

Novo Nordisk Widens Obesity Drug Gap as Lilly's Pill Launch Stumbles

Eli Lilly's obesity pill logged 1,390 first-week prescriptions versus Novo Nordisk's 3,071 in four days, as $NVO maintains commanding 113,354 weekly Wegovy prescriptions.
LLYNVOmarket sharepharmaceutical competition
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Eyes GLP-1 Market Share as Obesity Drug Sector Races to $100B

$VKING develops competing obesity drugs against $LLY and $NVO, with oral candidate entering phase 3 trials in Q3 2026 amid projected $100B market expansion.
LLYNVOVKTXbiotechclinical trials
The Motley FoolThe Motley Fool··Adria Cimino

Pharma Giant and Healthcare Insurer Offer Entry Points for Long-Term Investors

Pfizer and UnitedHealth Group present buying opportunities for $500 investors. Pfizer trades at 9x forward earnings with oncology growth plans; UnitedHealth at 15x after cost-cutting initiatives.
PFEUNHlong-term investingUnitedHealth Group
BenzingaBenzinga··Vandana Singh

HSBC Slashes Eli Lilly Price Target, Warns Obesity Drug Market Vastly Overhyped

HSBC downgraded $LLY to Reduce, citing inflated obesity market projections. The analyst sees $80-120B market by 2032, not Wall Street's $150B estimate.
LLYNVOprice target cutmarket valuation
The Motley FoolThe Motley Fool··Adria Cimino

Pfizer at a Crossroads: Patent Cliffs and Pipeline Bets Define Next Chapter

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.
PFELLYNVOclinical trialsacquisitions
The Motley FoolThe Motley Fool··Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk's Obesity Drug Underperforms Rival Zepbound in Late-Stage Trial

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.
LLYNVOclinical trialweight loss
BenzingaBenzinga··Vandana Singh

Viking Therapeutics Climbs on Competitive Positioning in Obesity Drug Race

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.
LLYNVORHHBYVKTXPhase 3 trialsweight loss
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Positioned for Market Expansion as Obesity Drug Sector Scales

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.
LLYNVOVKTXbiotechPhase 3 trial